A solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate is provided comprising amorphous nelfinavir mesylate, and a pharmaceutically acceptable, water soluble, non-ionic synthetic block copolymer of ethylene oxide and propylene oxide, said copolymer having a melting point of at least 400C. A hot melt granulation process for making the dosage form is provided.

Activated haptens useful for generating immunogens to HIV protease inhibitor s, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for HIV protease inhibitors. T he novel haptens feature an activated functionality at the central, non-terminal hydroxyl group common to all HIV protease inhibitors, e.g., saquinavir, nelfinavir, indinavir, amprenavir, ritonavir, lopinavir, and atazanavir.

A solid oral pharmaceutical dosage form of amorphous nelfinavir mesylate is provided comprising amorphous nelfinavir mesylate, and a pharmaceutically acceptable, water soluble, non-ionic synthetic block copolymer of ethylene oxide and propylene oxide, said polymer having a melting point of at least 40 degrees. A hot melt granulation process for making the dosage form is provided.